|
May 22
|
Earnings Estimates Rising for OptimizeRx (OPRX): Will It Gain?
|
|
May 13
|
OptimizeRx Corp (OPRX) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Shifts
|
|
May 12
|
OptimizeRx Corp. (OPRX) Beats Q1 Earnings and Revenue Estimates
|
|
May 12
|
OptimizeRx Reports First Quarter 2025 Financial Results and Updates Fiscal Year 2025 Guidance
|
|
May 1
|
OptimizeRx Releases 2025 Environmental, Social, and Governance (ESG) Report
|
|
Mar 13
|
OptimizeRx Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags
|
|
Mar 13
|
OptimizeRx Corp (OPRX) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Margin Expansion
|
|
Mar 13
|
Q4 2024 OptimizeRx Corp Earnings Call
|
|
Mar 12
|
OptimizeRx Corp. (OPRX) Q4 Earnings and Revenues Beat Estimates
|
|
Mar 12
|
OptimizeRx Reports Strong Fourth Quarter and Full Year 2024 Financial Results
|
|
Mar 11
|
OptimizeRx Corporation Confirms Receipt of Notice of Director Nominations
|
|
Mar 10
|
OptimizeRx Corporation Appoints Stephen Silvestro as Chief Executive Officer
|
|
Jan 2
|
Is There An Opportunity With OptimizeRx Corporation's (NASDAQ:OPRX) 49% Undervaluation?
|
|
Oct 3
|
OptimizeRx (OPRX) Moves 5.4% Higher: Will This Strength Last?
|
|
Sep 10
|
OptimizeRx Continues to Expand its Strategic Relationship with a Top-Tier Pharma Client via a Multi-Brand, Multi-Solution Investment Commitment with Over $10M In-Year Total Value
|
|
Sep 9
|
OptimizeRx Launches Novel Brand Eligibility Technology, Enabling Dynamic Direct to Consumer Marketing for Healthcare Audiences
|
|
Jul 25
|
OptimizeRx Sets Second Quarter 2024 Conference Call for August 8, 2024 at 4:30 p.m. ET
|
|
Jun 20
|
New White Paper Highlights How Closing the Health Information Gap Between Doctors and Patients Improves Life Science Marketing & Adds Value to Clinical Conversations
|
|
May 14
|
OptimizeRx Reports First Quarter 2024 Financial Results
|
|
May 13
|
Does OptimizeRx (OPRX) Have the Potential to Rally 34.78% as Wall Street Analysts Expect?
|